Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.32 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.32 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.32 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587413 | 0.77 | GRM5 (0.45) | GRM5CHRNB2ADRA2CCHRNB4CHRNA3 | |
| SCHEMBL5662057 | 0.77 | GRM5 (0.45) | GRM5CHRNB2ADRA2CCHRNB4CHRNA3 | |
| SCHEMBL14587411 | 0.77 | GRM5 (0.45) | GRM5CHRNB2ADRA2CCHRNB4CHRNA3 | |
| SCHEMBL7658515 | 0.77 | GRM5 (0.45) | GRM5CHRNB2ADRA2CCHRNB4CHRNA3 | |
| SCHEMBL7655571 | 0.77 | GRM5 (0.45) | GRM5CHRNB2ADRA2CCHRNB4CHRNA3 | |
| SCHEMBL6964387 | 0.73 | GRM5 (0.46) | GRM5CHRNB2ADRA2CCHRNB4CHRNA3 | |
| SCHEMBL2836304 | 0.73 | GRM5 (0.43) | GRM5CHRNB2ADRA2CCHRNB4CHRNA3 | |
| SCHEMBL7840974 | 0.73 | GRM5 (0.43) | GRM5CHRNB2ADRA2CCHRNB4CHRNA3 | |
| SCHEMBL6963296 | 0.73 | GRM5 (0.43) | GRM5CHRNB2ADRA2CCHRNB4CHRNA3 | |
| SCHEMBL7078062 | 0.72 | HTR2A (0.39) | KDM1AMAOBSIRT2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620815-B1 | Selective antagonists for human alpha 1A receptors; benign prostatic hyperplasia, impotency, cardiac arrhythmia treatment; anticholesterol agents; intraocular pressure reduction | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-16 | — | — | US | disclosed |
| EP-0988295-A4 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-0998285-A4 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6255315-B1 | BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2001-07-03 | — | — | US | disclosed |
| US-6159990-A | Oxazolidinones as α1A receptor antagonists | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000027816-A1 | OXAZOLIDINONES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| EP-0998285-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-05-10 | — | — | EP | disclosed |
| EP-0988295-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-29 | — | — | EP | disclosed |
| US-6037354-A | ADMINISTERING PHENYL-SUBSTITUTED THIAZOLIDIN-4-ONE OR OXAZOLIDIN-2-ONE DERIVATIVE TO TREAT BENIGN PROSTATE HYPERPLASIA; SIDE EFFECT REDUCTION | MERCK & CO., INC. (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1998057940-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998057641-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-12-23 | — | — | WO | disclosed |